Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 74Terminated 21Recruiting 17Unknown 11Active not recruiting 10Withdrawn 4Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1Genitourinary 1

Conditions

Pancreatic Neoplasms 27Carcinoma, Non-Small-Cell Lung 15Neoplasms 6Lung Neoplasms 6Cholangiocarcinoma 6Carcinoma, Hepatocellular 5Sarcoma 4Neoplasm Metastasis 4Bone Neoplasms 4Recurrence 3Ovarian Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Histiocytoma, Malignant Fibrous 3Dermatofibrosarcoma 3Biliary Tract Neoplasms 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma, Synovial 2Rhabdomyosarcoma 2Neoplasms, Unknown Primary 2Lymphoma, T-Cell 2Lymphoma, B-Cell 2Liposarcoma 2Leiomyosarcoma 2Hodgkin Disease 2Hemangiosarcoma 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

Radiosurgery 7Oxaliplatin 7Docetaxel 7Paclitaxel 5Fluorouracil 5Nivolumab 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Carboplatin 4Capecitabine 4Trastuzumab 3Radiotherapy 3Radiation 3Leucovorin 3Erlotinib Hydrochloride 3Cyclophosphamide 3Cetuximab 3Bevacizumab 3spartalizumab 2sipuleucel-T 2repotrectinib 2pembrolizumab 2pazopanib 2orteronel 2fludarabine 2atezolizumab 2aldesleukin 2Temozolomide 2Surveys and Questionnaires 2Sunitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × Neoplasm Metastasis × Gemcitabine × Clear all
NCT02105350 2018-02-19

A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer

University Health Network, Toronto

Phase 1 Withdrawn
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Recurrence

NCT01830322 2013-08-14

Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer

Cornerstone Pharmaceuticals

Phase 2 Withdrawn
Tumor-Agnostic

Adenocarcinoma, Neoplasm Metastasis, Neoplasms

NCT01600807 2013-06-26

OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

Dana-Farber Cancer Institute

Phase 1/2 Withdrawn
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT01834183 2013-06-19

Tivozanib + Gemcitabine in Metastatic RCC

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡